BLUEPRINT MEDICINES CORP (BPMC)
US09627Y1091 - Common Stock
First Week of BPMC February 2025 Options Trading
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview...
BPMC Makes Bullish Cross Above Critical Moving Average
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations that continue to demonstrate the long-term clinical benefits...
Noteworthy Friday Option Activity: PG, APLT, BPMC
BPMC Makes Bullish Cross Above Critical Moving Average
Noteworthy Monday Option Activity: SATS, RXST, BPMC
Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the third quarter ended Sept...
Notable Friday Option Activity: INSM, ORA, BPMC
Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024
/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on...
Blueprint Medicines to Present at Upcoming Investor Conferences
/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming virtual investor conferences: Stifel...
Blueprint Medicines Enters Oversold Territory (BPMC)
BPMC Crosses Below Key Moving Average Level
Blueprint Medicines Breaks Below 200-Day Moving Average - Notable for BPMC
Blueprint Medicines is Now Oversold (BPMC)
Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the second quarter ended June...
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on...
Noteworthy Friday Option Activity: CAR, DBRG, BPMC
Noteworthy Tuesday Option Activity: DBI, BPMC, NOW
Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced multiple upcoming datasets across two key conferences that reinforce the...
Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced updated data from the ongoing Phase 1 dose escalation portion of the VELA...
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective May 1, 2024, the Compensation Committee of Blueprint Medicines'...
BPMC Stock Earnings: Blueprint Medicines Beats EPS, Beats Revenue for Q1 2024
BPMC stock results show that Blueprint Medicines beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.